Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

PD1 Non-Small Cell Lung Cancer Treatment Market Snapshot (2023 to 2033)

The global PD1 non-small cell lung cancer treatment market size is expected to surpass an impressive valuation of US$ 26.96 Billion in 2023 and is projected to reach US$ 61 Billion by 2033, growing at a CAGR of 8.51%

The presence of a strong pipeline for NSCLC is projected to propel growth over the coming years. For instance, fruquintinib (HMPL-013), a drug developed to treat advanced non-small cell lung cancer is in the clinical trial phase. Furthermore, Avelumab developed by Merck KGaA is currently in the pipeline. It is a fully human monoclonal PD-L1 antibody. Thus, the development of such advanced treatments is expected to drive the market during the forecast period.

High growth is attributed to the growing patient population, expected entry of several drugs, and increasing investment by industry players in the Research and Development (R&D) of NSCLC therapy. The increasing prevalence of NSCLC across the globe owing to increasing air pollution and smoking habits amongst people is likely to propel market growth over the coming years.

Report Attribute Details
Expected Market Value (2023) US$ 26.96 Billion
Anticipated Forecast Value (2033) US$ 61 Billion
Projected Growth Rate (2023 to 2033) CAGR 8.51%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 PD1 Non-Small Cell Lung Cancer Treatment Demand Analysis vs. Forecast 2023 to 2033

The market revenue for PD1 Nonsmall cell lung cancer treatment was US$ 18.2 Billion in 2018 while exhibiting a CAGR of 5.7%. Pharmaceutical companies have begun to develop additional anti-PD-1/PD-L1 antibodies to overcome resistance and are devising further immunotherapy combinations which is creating space for market expansion. More than 20 anti-PD-1/PD-L1 antibodies have been approved or are currently in development. Numerous combination therapies are under development, and several combination therapies have provided positive results in randomized controlled trials which presents growth avenues for the market.

The global increase in cancer cases boosts the global non-small cell lung cancer market during the forecast period. According to American Cancer Society statistics from 2020, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a global death rate of 30,000 per year.

Furthermore, according to WHO data, lung cancer is the second most common cancer in men and women, accounting for around 3 million deaths in 2020. This boosts the market growth. Thus, considering these factors and developments, FMI has estimated the market to gross a value of US$ 61 Billion with a CAGR of 8.51% by end of the forecast period.

Which are Some Prominent Drivers of the PD1 Non-small cell lung cancer treatment market?

New drug approvals to fuel market growth

The rising number of new drug approvals by regulatory authorities for the treatment of non-small cell lung cancer is anticipated to drive the growth of the market. For instance, in May 2019, Pfizer Inc., which is a USA-based multinational pharmaceutical and biotechnology corporation received the European Commission’s (EC) marketing authorization for the LORVIQUA drug, a monotherapy drug used for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This development will aid in market growth.

Moreover, with the approval of Nivolumab, immune-checkpoint inhibitors (ICIs), mainly anti-programmed cell death-1 (PD-1) antibodies, have rapidly revolutionized cancer treatment which is anticipated to drive the market in the forecast period. The recommendation of combination therapy with an anti-PD-1/PD-L1 antibody and platinum-based chemotherapy as a first-line therapy for patients with advanced NSCLC without driver gene mutations will augment the growth of the PD1 Non-small cell lung cancer treatment market during the forecast period

Rising demand for oral drugs to augment product demand

Oral drugs are expected to boost the market growth. The segment is estimated to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Lack of skilled professionals restraining market growth

The dearth of trained professionals who are unaware of treatment methods for this disease may restrict the growth of the global PD1 non-small cell lung cancer treatment market during the forecast period.

High cost of treatment to hamper market expansion

The high cost of drugs is a major blockade for patients to adopt these drugs easily. Thus, presenting challenges for market expansion.

Region-Wise Insights

What is the growth outlook in North America?

North America rules the market with the highest market share

This region is expected to dominate the market with a market share of 42% during the forecast period. The market in the USA was estimated at US$ 9.2 Billion in 2022. The growth is attributed due to increasing support from the U.S. Government for developing therapies and drugs to treat different types of cancer. The availability of state-of-the-art research facilities and access to advanced testing equipment helps with successful research, which is contributing to market growth.

Furthermore, high research and development activities, the launch of companion diagnostics by industry players, and massive healthcare spending are propelling the growth of the overall regional market to a large extent. ?The cost of treatment which includes chemotherapy, immunotherapy, targeted therapy, radiation, and in some cases, surgery, is vast, and the availability of significant reimbursement in the region is likely to augment market growth.

What are the growth prospects in South Asia?

South Asia to witness the fastest growth in the forecast period

This region is expected to witness the fastest CAGR of 8% in the forecast period. The market in this region is projected to account for 25.5% of revenue by 2033. China is expected to grow at a CAGR of 13.7% with a market valuation to reach US$ 12.2 Billion by end of the forecast period. The growth in this region is attributable to the presence of a large patient population and the rise in research and development activities in the pharmaceutical sector.

Moreover, the presence of companies and growth in the purchasing power of countries like India and China will fuel product demand. Also, the rise in the adoption of therapies for cancer and the adoption of high-tech processing to improve training programs are driving growth in this region.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

By Treatment Type, which segment is most likely to dominate the market?

Demand for Targeted Cancer Therapies on the Rise

Targeted therapy is expected to dominate the market by reaching a valuation of US$ 31.7 Billion by end of the forecast period while exhibiting a CAGR of 10%. This segment is expected to continue this trend owing to distinct clinical benefits offered by this therapy such as minimal side effects along with the availability of a number of targeted therapeutics.

In addition, rise in the number of people turning to targeted therapy as a form of treatment for cancer, and targeted therapy is successful in up to 80% of cases. These factors will propel the segment’s growth in the upcoming years.

By Distribution Channel, which segment will possess the highest market share?

Hospital Pharmacies account for the Maximum Availability of key Drugs

This segment is expected to account for 52% market share while trailing at a CAGR of 12% during the forecast period. The dominance is due to an increase in the number of hospitalizations of patients suffering from PD1 Non-small cell lung cancer and the presence of skilled professionals within these settings.

Start-ups in PD1 Non-small cell lung cancer treatment market

  • Founded in 2016, ‘Ikena Oncology’ is a USA-based start-up that develops biomarker-based therapies for treating cancer. The lead product candidate IK-007 is currently in clinical development for the treatment of microsatellite stable colorectal cancer and PD-1/L1 refractory non-small cell lung cancer. The other drug candidates include IK-930 for Hippo-mutated cancers and solid tumors, IK-1751 for bladder cancer, and others. It received a total funding of USD 168 million from Omega Funds, Fidelity Investments, and 10 others.
  • Founded in 2012, ‘Junshi’ Biopharma is a shanghai-based company that provides antibody-based therapeutics for multiple diseases. The company's drug candidates include anti-PD-1 monoclonal antibodies, PCSK9 monoclonal antibodies, anti-BLyS monoclonal antibodies, and others for the treatment of cancer, metabolic, neurology, immunology, and infectious diseases.

Market Competition

The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost the market growth. The major players in the market are Merck Co. & Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, AstraZeneca Plc, Pfizer Inc, Merck KGaA, Novartis AG, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Sanofi, and Agennix AG. Some recent developments in this industry are:

  • In January 2021, The Lung Ambition Alliance, which is a global coalition with the bold ambition to eliminate lung cancer as a cause of death, started The Initiatives in Lung Cancer Care (ILC2) program. The aim of the program is to fund projects that drive measurable improvements across the patient journey, from early detection to palliative care or survivorship.
  • In August 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.
  • In March 2022, Regeneron and BioNTech expanded their collaboration agreement for the development of Libtayo and FixVac (cemiplimab) Combination to treat advanced NSCLC.
  • In 2021, Daiichi Sankyo received FDA approval for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 26.96 Billion
Market Value in 2033 US$ 61 Billion
Growth Rate CAGR of 8.51% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Treatment
  • Drug Type
  • Cancer Type
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • The USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Merck Co. & Inc.
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche AG
  • AstraZeneca Plc.
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Sanofi
  • Agennix AG
Customization Available Upon Request

Key Segments Profiled in the PD1 Non-small Cell Lung Cancer Treatment Market Industry survey

By Drug Type:

  • Nivolumab
  • Pembrolizumab
  • Atezolizumab
  • Avelumab
  • Durvalumab

By Cancer Type:

  • Squamous Cell carcinoma
  • Adenocarcinoma
  • Large-cell carcinoma

By Treatment:

  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What was the Historical Size of the Market?

The market witnessed a CAGR of 5.7% from 2018 to 2022.

What is the Expected Value of the Market?

The market is expected to reach US$ 31.7 billion through 2033.

What is the Growth Outlook for Hospital Pharmacies?

The hospital pharmacies segment is estimated to register a growth rate of 12% until 2033.

What is North America's Growth Outlook?

North America’s market is expected to dominate with a market share of 42%.

What is the Present Market Value in 2023?

The market is valued at US$ 26.96 billion in 2023.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Nivolumab

        5.3.2. Pembrolizumab

        5.3.3. Atezolizumab

        5.3.4. Avelumab

        5.3.5. Durvalumab

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ million) Analysis By Cancer Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Cancer Type, 2023 to 2033

        6.3.1. Squamous Cell Carcinoma

        6.3.2. Adenocarcinoma

        6.3.3. Large-cell Carcinoma

    6.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Cancer Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ million) Analysis By Treatment, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Treatment, 2023 to 2033

        7.3.1. Chemotherapy

        7.3.2. Targeted Therapy

        7.3.3. Immunotherapy

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. The USA

            10.2.1.2. Canada

        10.2.2. By Drug Type

        10.2.3. By Cancer Type

        10.2.4. By Treatment

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Cancer Type

        10.3.4. By Treatment

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Type

        11.2.3. By Cancer Type

        11.2.4. By Treatment

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Cancer Type

        11.3.4. By Treatment

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. The United Kingdom

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug Type

        12.2.3. By Cancer Type

        12.2.4. By Treatment

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Cancer Type

        12.3.4. By Treatment

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Drug Type

        13.2.3. By Cancer Type

        13.2.4. By Treatment

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Cancer Type

        13.3.4. By Treatment

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Type

        14.2.3. By Cancer Type

        14.2.4. By Treatment

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Cancer Type

        14.3.4. By Treatment

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Drug Type

        15.2.3. By Cancer Type

        15.2.4. By Treatment

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Cancer Type

        15.3.4. By Treatment

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Drug Type

        16.2.3. By Cancer Type

        16.2.4. By Treatment

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug Type

        16.3.3. By Cancer Type

        16.3.4. By Treatment

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. The USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Drug Type

            17.1.2.2. By Cancer Type

            17.1.2.3. By Treatment

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Drug Type

            17.2.2.2. By Cancer Type

            17.2.2.3. By Treatment

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Drug Type

            17.3.2.2. By Cancer Type

            17.3.2.3. By Treatment

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Drug Type

            17.4.2.2. By Cancer Type

            17.4.2.3. By Treatment

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Drug Type

            17.5.2.2. By Cancer Type

            17.5.2.3. By Treatment

            17.5.2.4. By Distribution Channel

    17.6. U.K.

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Drug Type

            17.6.2.2. By Cancer Type

            17.6.2.3. By Treatment

            17.6.2.4. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Drug Type

            17.7.2.2. By Cancer Type

            17.7.2.3. By Treatment

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Drug Type

            17.8.2.2. By Cancer Type

            17.8.2.3. By Treatment

            17.8.2.4. By Distribution Channel

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Drug Type

            17.9.2.2. By Cancer Type

            17.9.2.3. By Treatment

            17.9.2.4. By Distribution Channel

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Drug Type

            17.10.2.2. By Cancer Type

            17.10.2.3. By Treatment

            17.10.2.4. By Distribution Channel

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Drug Type

            17.11.2.2. By Cancer Type

            17.11.2.3. By Treatment

            17.11.2.4. By Distribution Channel

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Drug Type

            17.12.2.2. By Cancer Type

            17.12.2.3. By Treatment

            17.12.2.4. By Distribution Channel

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Drug Type

            17.13.2.2. By Cancer Type

            17.13.2.3. By Treatment

            17.13.2.4. By Distribution Channel

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Drug Type

            17.14.2.2. By Cancer Type

            17.14.2.3. By Treatment

            17.14.2.4. By Distribution Channel

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Drug Type

            17.15.2.2. By Cancer Type

            17.15.2.3. By Treatment

            17.15.2.4. By Distribution Channel

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Drug Type

            17.16.2.2. By Cancer Type

            17.16.2.3. By Treatment

            17.16.2.4. By Distribution Channel

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Drug Type

            17.17.2.2. By Cancer Type

            17.17.2.3. By Treatment

            17.17.2.4. By Distribution Channel

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Drug Type

            17.18.2.2. By Cancer Type

            17.18.2.3. By Treatment

            17.18.2.4. By Distribution Channel

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Drug Type

            17.19.2.2. By Cancer Type

            17.19.2.3. By Treatment

            17.19.2.4. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Drug Type

            17.20.2.2. By Cancer Type

            17.20.2.3. By Treatment

            17.20.2.4. By Distribution Channel

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Drug Type

            17.21.2.2. By Cancer Type

            17.21.2.3. By Treatment

            17.21.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Drug Type

        18.3.3. By Cancer Type

        18.3.4. By Treatment

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Merck Co. & Inc.

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Bristol-Myers Squibb

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. F. Hoffmann-La Roche AG

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. AstraZeneca Plc.

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Pfizer Inc.

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Merck KGaA

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Novartis AG

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. GlaxoSmithKline plc.

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Takeda Pharmaceutical Company Limited

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Eli Lilly and Company

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

        19.1.11. Sanofi

            19.1.11.1. Overview

            19.1.11.2. Product Portfolio

            19.1.11.3. Profitability by Market Segments

            19.1.11.4. Sales Footprint

            19.1.11.5. Strategy Overview

                19.1.11.5.1. Marketing Strategy

        19.1.12. Agennix AG

            19.1.12.1. Overview

            19.1.12.2. Product Portfolio

            19.1.12.3. Profitability by Market Segments

            19.1.12.4. Sales Footprint

            19.1.12.5. Strategy Overview

                19.1.12.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 3: Global Market Value (US$ million) Forecast by Cancer Type, 2018 to 2033

Table 4: Global Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 5: Global Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 6: North America Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 7: North America Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 8: North America Market Value (US$ million) Forecast by Cancer Type, 2018 to 2033

Table 9: North America Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 10: North America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 11: Latin America Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 12: Latin America Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 13: Latin America Market Value (US$ million) Forecast by Cancer Type, 2018 to 2033

Table 14: Latin America Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 15: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 16: Europe Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 17: Europe Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 18: Europe Market Value (US$ million) Forecast by Cancer Type, 2018 to 2033

Table 19: Europe Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 20: Europe Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 21: South Asia Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 22: South Asia Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 23: South Asia Market Value (US$ million) Forecast by Cancer Type, 2018 to 2033

Table 24: South Asia Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 25: South Asia Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 26: East Asia Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 27: East Asia Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 28: East Asia Market Value (US$ million) Forecast by Cancer Type, 2018 to 2033

Table 29: East Asia Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 30: East Asia Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 31: Oceania Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 32: Oceania Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 33: Oceania Market Value (US$ million) Forecast by Cancer Type, 2018 to 2033

Table 34: Oceania Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 35: Oceania Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 36: MEA Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 37: MEA Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 38: MEA Market Value (US$ million) Forecast by Cancer Type, 2018 to 2033

Table 39: MEA Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 40: MEA Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 2: Global Market Value (US$ million) by Cancer Type, 2023 to 2033

Figure 3: Global Market Value (US$ million) by Treatment, 2023 to 2033

Figure 4: Global Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 5: Global Market Value (US$ million) by Region, 2023 to 2033

Figure 6: Global Market Value (US$ million) Analysis by Region, 2018 to 2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 9: Global Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 12: Global Market Value (US$ million) Analysis by Cancer Type, 2018 to 2033

Figure 13: Global Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033

Figure 14: Global Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033

Figure 15: Global Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 16: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 17: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 18: Global Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 21: Global Market Attractiveness by Drug Type, 2023 to 2033

Figure 22: Global Market Attractiveness by Cancer Type, 2023 to 2033

Figure 23: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 25: Global Market Attractiveness by Region, 2023 to 2033

Figure 26: North America Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 27: North America Market Value (US$ million) by Cancer Type, 2023 to 2033

Figure 28: North America Market Value (US$ million) by Treatment, 2023 to 2033

Figure 29: North America Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 30: North America Market Value (US$ million) by Country, 2023 to 2033

Figure 31: North America Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 34: North America Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 37: North America Market Value (US$ million) Analysis by Cancer Type, 2018 to 2033

Figure 38: North America Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033

Figure 39: North America Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033

Figure 40: North America Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 41: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 42: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 43: North America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 46: North America Market Attractiveness by Drug Type, 2023 to 2033

Figure 47: North America Market Attractiveness by Cancer Type, 2023 to 2033

Figure 48: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 50: North America Market Attractiveness by Country, 2023 to 2033

Figure 51: Latin America Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 52: Latin America Market Value (US$ million) by Cancer Type, 2023 to 2033

Figure 53: Latin America Market Value (US$ million) by Treatment, 2023 to 2033

Figure 54: Latin America Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 55: Latin America Market Value (US$ million) by Country, 2023 to 2033

Figure 56: Latin America Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 59: Latin America Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 62: Latin America Market Value (US$ million) Analysis by Cancer Type, 2018 to 2033

Figure 63: Latin America Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033

Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033

Figure 65: Latin America Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 66: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 68: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 71: Latin America Market Attractiveness by Drug Type, 2023 to 2033

Figure 72: Latin America Market Attractiveness by Cancer Type, 2023 to 2033

Figure 73: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 76: Europe Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 77: Europe Market Value (US$ million) by Cancer Type, 2023 to 2033

Figure 78: Europe Market Value (US$ million) by Treatment, 2023 to 2033

Figure 79: Europe Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 80: Europe Market Value (US$ million) by Country, 2023 to 2033

Figure 81: Europe Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 84: Europe Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 87: Europe Market Value (US$ million) Analysis by Cancer Type, 2018 to 2033

Figure 88: Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033

Figure 89: Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033

Figure 90: Europe Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 91: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 92: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 93: Europe Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 96: Europe Market Attractiveness by Drug Type, 2023 to 2033

Figure 97: Europe Market Attractiveness by Cancer Type, 2023 to 2033

Figure 98: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 99: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: South Asia Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 102: South Asia Market Value (US$ million) by Cancer Type, 2023 to 2033

Figure 103: South Asia Market Value (US$ million) by Treatment, 2023 to 2033

Figure 104: South Asia Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 105: South Asia Market Value (US$ million) by Country, 2023 to 2033

Figure 106: South Asia Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 109: South Asia Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 110: South Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 112: South Asia Market Value (US$ million) Analysis by Cancer Type, 2018 to 2033

Figure 113: South Asia Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033

Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033

Figure 115: South Asia Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 116: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 118: South Asia Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 119: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 121: South Asia Market Attractiveness by Drug Type, 2023 to 2033

Figure 122: South Asia Market Attractiveness by Cancer Type, 2023 to 2033

Figure 123: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 124: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 126: East Asia Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 127: East Asia Market Value (US$ million) by Cancer Type, 2023 to 2033

Figure 128: East Asia Market Value (US$ million) by Treatment, 2023 to 2033

Figure 129: East Asia Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 130: East Asia Market Value (US$ million) by Country, 2023 to 2033

Figure 131: East Asia Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 134: East Asia Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 135: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 137: East Asia Market Value (US$ million) Analysis by Cancer Type, 2018 to 2033

Figure 138: East Asia Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033

Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033

Figure 140: East Asia Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 141: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 143: East Asia Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 144: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 146: East Asia Market Attractiveness by Drug Type, 2023 to 2033

Figure 147: East Asia Market Attractiveness by Cancer Type, 2023 to 2033

Figure 148: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 149: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 151: Oceania Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 152: Oceania Market Value (US$ million) by Cancer Type, 2023 to 2033

Figure 153: Oceania Market Value (US$ million) by Treatment, 2023 to 2033

Figure 154: Oceania Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 155: Oceania Market Value (US$ million) by Country, 2023 to 2033

Figure 156: Oceania Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 159: Oceania Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 160: Oceania Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 162: Oceania Market Value (US$ million) Analysis by Cancer Type, 2018 to 2033

Figure 163: Oceania Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033

Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033

Figure 165: Oceania Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 166: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 168: Oceania Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 169: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 171: Oceania Market Attractiveness by Drug Type, 2023 to 2033

Figure 172: Oceania Market Attractiveness by Cancer Type, 2023 to 2033

Figure 173: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 174: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 176: MEA Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 177: MEA Market Value (US$ million) by Cancer Type, 2023 to 2033

Figure 178: MEA Market Value (US$ million) by Treatment, 2023 to 2033

Figure 179: MEA Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 180: MEA Market Value (US$ million) by Country, 2023 to 2033

Figure 181: MEA Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 184: MEA Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 187: MEA Market Value (US$ million) Analysis by Cancer Type, 2018 to 2033

Figure 188: MEA Market Value Share (%) and BPS Analysis by Cancer Type, 2023 to 2033

Figure 189: MEA Market Y-o-Y Growth (%) Projections by Cancer Type, 2023 to 2033

Figure 190: MEA Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 191: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 192: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 193: MEA Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 196: MEA Market Attractiveness by Drug Type, 2023 to 2033

Figure 197: MEA Market Attractiveness by Cancer Type, 2023 to 2033

Figure 198: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 199: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 200: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Non-Small Cell Lung Carcinoma (NSCLC) Market

Published : December 2022

Healthcare

Non-Small Cell Lung Cancer Market

Published : December 2022

Healthcare

Lung Cancer Surgery Market

Published : June 2022

Healthcare

Lung Cancer Therapeutics Market

Published : June 2022

Explore Healthcare Insights

View Reports

PD1 Non-Small Cell Lung Cancer Treatment Market